

9/13/22

Agenda

- Speaker: Influenza and COVID-19 updates
- Case Discussions
- Open Discussion






- Influenza Epi update JBL
- Influenza vaccine-RJ
- COVID Boosters –ZKE
- Respiratory virus testing-CBC



CDC FLU 2016-2020

FIGURE 1. Number of respiratory specimens tested and percentage testing positive for influenza, by year — United States, 2016–17 through 2019–20 seasons




Source: FluView Interactive. https://www.cdc.gov/flu/weekly/fluviewinteractive.htm.



WHO FluNet

Virus detections by subtype reported to FluNet



Non-sentinel: Data obtained from non-sentinel systems as indicated by the reporting country. Data reported in this category may include outbreak investigation, universal testing, testing at point of care or other systems apart from sentinel surveillance.
 Sentinel: Data obtained from sentinel surveillance as indicated by the reporting country. Sentinel surveillance systems collect high-quality data in a timely manner systematically and routinely from sentinel surveillance sites representatives of the population under surveillance.
 Type not defined: Source of data not indicated by the reporting country neither as sentinel surveillance. These data may include sentinel surveillance sources or both.

© Copyright World Health Organization (WHO) [2022]. All Rights Reserved


Calendar type: ISO 8601

Data source: FluNet (https://www.who.int/tools/flunet)




CDC FLUVIEW

Influenza Positive Tests Reported to CDC by U.S. Clinical Laboratories, National Summary, October 3, 2021 – September 3, 2022




CDC FLU Hospitalizations



Calendar Week Ending (MMWR Week No.)

EIP :: Oregon :: 2021-22 :: Weekly Rate To zoom, hold down Alt key and click and drag to create a rectangle. Double click to reset zoom.


Calendar Week Ending (MMWR Week No.)





FLU Forecast?

Influenza in Australia in 2022?






Normal.dot (health.gov.au)

CDC FLU Forecast (Hospitalizations)

National Forecast





Influenza vaccines

Core recommendation (unchanged):

 Annual influenza vaccination is recommended for all persons aged 6 months and older who do not have contraindications.

Updates on the following topics:

- Change in FDA-approved age indication for Flucelvax Quadrivalent from ≥ 2 years to ≥ 6 months.
- Updated recommendations for vaccination of persons aged ≥65 years.

https://emergency.cdc.gov/coca/ppt/2022/090822_slides.pdf



Influenza Vaccines by Age Indication, United States, 2022–23 Influenza Season

Vaccine type		0 through 6 months	6 through 23 months	2 through 17 years	18 through 49 years	50 through 64 years	≥65 years
llV4s	Standard-dose, unadjuvanted inactivated (IIV4)		Afluria Quadrivalent Fluarix Quadrivalent FluLaval Quadrivalent Fluzone Quadrivalent				
	Cell culture-based inactivated (ccIIV4)		Flucelvax Quadrivalent				
	Adjuvanted inactivated (allV4)	Fluad Quadrivalent					
	High-dose inactivated (HD-IIV4)	Fluzone High-Dose Quadrivalent					
RIV4	Recombinant (RIV4)		Flublok Quadrivalent				
LAIV4	Live attenuated (LAIV4)			FluMist Qu	adrivalent		

Not approved for age group

Egg-based

Not egg-based

All vaccines expected for 2022-23 are quadrivalent (i.e., contain hemagglutinin derived from four viruses: 19 one influenza A(H1N1), one influenza A(H3N2), one influenza B/Victoria and one influenza B/Yamagata.

What is adjuvanted mean?

What is MF59?

MF59 is an oil-in-water emulsion of squalene oil. Squalene, a naturally occurring substance found in humans, animals, and plants, is highly purified for the vaccine manufacturing process.

Why are adjuvants added to flu vaccines?

An adjuvant is an ingredient of some vaccines that helps promote a better immune response. Adjuvants also can reduce the amount of virus needed for production of a vaccine, which can allow for greater supplies of vaccine to be manufactured.



Data for <a>> 65 years

- Overall, there is evidence of greater potential benefit over standard dose.
 - Most evidence for HD-Fluzone.
 - Less evidence for Flubok and FluAD;
- •Few studies compare vaccines approved for <a>> 65 years with one another
 - -insufficient to conclude that any one vaccine will be superior to the others across seasons.
- Limitations include:
 - Few randomized studies, covering few influenza seasons.
 - More data from observational studies, most are retrospective cohort designs using diagnostic code defined outcomes.
 - No data reflecting currently available formulations.

COVID-19 boosters



On August 31, 2022:

- Moderna COVID-19 Vaccine, Bivalent authorized for use in people ages 18 years and older.
- Pfizer-BioNTech COVID-19 Vaccine, Bivalent authorized for use in people ages 12 years and older



Fall Booster "Reset"

- Recommendations are simplified
- Change from dose counting to 1 bivalent booster for everyone eligible
- If eligible, a bivalent should not be denied based on total number of doses

Vaccination history	\rightarrow	Next dose
Primary series	At least 2 months	1 bivalent booster dose
Primary series + 1 booster	At least 2 months	1 bivalent booster dose
Primary series + 2 booster	At least 2 months	1 bivalent booster dose


https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2022-09-01/09-COVID-Hall-508.pdf



COVID-19 Vaccination Schedule for People who are NOT Moderately or Severely Immunocompromised

People ages 12 years and older At least 3-8 or 4-8 Moderna, 2 months weeks* **Bivalent** Primary Primary Novavax, or Dose Booster[†] Dose Pfizer-BioNTech **Primary Series** Regardless of previous monovalent booster doses given

People ages 18 years and older




*3-8 interval for Novavax and Pfizer-BioNTech; 4-8 interval for Moderna

⁺The bivalent booster dose is administered at least 2 months after completion of the primary series.

For people who previously received a monovalent booster dose(s), the bivalent booster dose is administered at least 2 months after the last monovalent booster dose. The bivalent booster should be age appropriate; Pfizer-BioNTech is authorized for people ages 12 years and older and Moderna is authorized for people ages 18 years and older.



COVID-19 Vaccination Schedule for People who ARE Moderately or Severely Immunocompromised





Timing Considerations for People with Current or Prior SARS-CoV-2 Infection

- At a minimum, defer any COVID-19 vaccination, including bivalent booster vaccination, at least until recovery from the acute illness (if symptoms were present) and criteria to discontinue isolation have been met.
- In addition, people who recently had SARS-CoV-2 infection may consider delaying any COVID-19 vaccination, including bivalent booster vaccination, by 3 months from symptom onset or positive test (if infection was asymptomatic).
- Individual factors such as risk of COVID-19 severe disease, COVID-19 community level, or characteristics of the predominant SARS-CoV-2 strain should be taken into account when determining whether to delay getting a COVID-19 vaccination after infection.



Manufacturer	Pfizer€	Moderna	
Formulation	Bivalent	Bivalent	
Age group	≥12yo	≥18yo	
Vial image		Anderna COVID-IT Anderna COVID-IT Anderna COVID-IT Andrea and Sivaler Andrea and Sivaler Andrea and Siral Andrea Andrea and Siral Andrea	
Booster Dose	(15 mcg + 15 mcg)	(25 mcg + 25 mcg) /	
	/0.3 mL	0.5 mL	
Diluent per vial	No Dilution	No Dilution	
Doses per vial	6 doses per vial	5 doses per vial	
Protect from light during storage	Yes	Yes	
Ultra-Low-Temp Freezer [-90C to -60C]	12 months ^{\dagger}	Do Not Store	
Freezer [-50C to -15C]	Do Not Store	Until expiration date [¥]	
Refrigerator (unpunctured) [2C to 8C]	70 days	30 days	
Room Temp (unpunctured) [8C to 25C]	12 hours (<u>including</u> thaw time)	24 hours	
After First Puncture	Discard after	Discard after	
	12 hours	12 hours	
edical Center Pharmacy Services	(RT or refrigerated)	(RT or refrigerated)	

[€]Pfizer vaccine info excerpted from https://www.cvdvaccine-us.com/

[†]Regardless of storage condition, vaccines should not be used after 12 months from the date of manufacture printed on the vial and cartons.

^{*}Confirm Moderna vaccine manufacturer expiration date by looking up lot number at https://eua.modernatx.com/covid19vaccineeua/providers/vial-lookup?#vialLookUpTool.

Updated 9.6.22 CMW, Harborview Medical Center Pharmacy Services



- Monovalent mRNA COVID-19 vaccines are no longer authorized for use as boosters in individuals ≥ 12 years
- Bivalent vaccines contain an mRNA component from the original strain + an mRNA component derived from Omicron BA.4/BA.5
- Immune response to Omicron strains is enhanced in people who receive the bivalent booster compared to the monovalent booster
- Safety data from 800 individuals who received a bivalent vaccine with the original strain + Omicron BA.1
- Most commonly reported side effects included pain, redness and swelling at the injection site, fatigue, headache, muscle pain, chills, joint pain, and fever.

Washington Department of Health. COVID-19 Vaccine Partner Newsletter. September 2, 2022 US Food and Drug Administration. COVID-19 Update: FDA Authorizes Moderna, Pfizer-BioNTech Bivalent COVID-19 Vaccines for Use as a Booster Dose. August 31, 2022

Coadministration of Influenza with COVID-19 Vaccine

- ✓ Providers should offer influenza and COVID-19 vaccines at the same visit, if eligible.
 - This includes adjuvanted or high-dose influenza vaccines; administer in separate limbs.
- ✓ Extensive experience with non-COVID 19 vaccines has demonstrated that immunogenicity and adverse event profiles are generally similar when vaccines are administered simultaneously as when they are administered alone.
- ✓ With both influenza and SARS-CoV-2 circulating, getting both vaccines is important for prevention of severe disease, hospitalization, and death.



How to Test When SARS-CoV-2 and Influenza are Co-Circulating

Patient with Acute Respiratory Illness						
	Admitted to Hospital	Outpatient	Long-Term Care			
SARS-CoV-2	TEST	TEST	TEST			
Influenza	TEST	Only if it will change management*	TEST			
How?	Multiplex or individually	Multiplex or individually	Multiplex or individually			

*Infection control (e.g. lives in congregate setting) OR treatment decisions (e.g. at risk for a complication of influenza)

Testing Guidance for Clinicians When SARS-CoV-2 and Influenza Viruses are Co-circulating (cdc.gov

Who Should Be Treated for Flu (suspect or confirmed)

Regardless of Duration

- Hospitalized
- Progressive/severe disease
- Chronic medical condition
 BMI >40, immunosuppressed, lung renal heart liver hematologic neuromuscular dz, diabetes
- <2 or ≥ 65 years
- Pregnant or < 2 weeks postpartum

Consider if $Sx \le 2$ days

- Outpatients
- Household contact is a person at high risk of developing a complication (especially immunocompromised)
- Symptomatic healthcare providers

